NCT03390673View on ClinicalTrials.gov

To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

September 19, 2018

Primary Completion Date

March 13, 2019

Study Completion Date

March 13, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

HD204

Single-Dose 1mg/kg body weight by 90 minute intravenous infusion

DRUG

Avastin

Single-Dose 1mg/kg body weight by 90 minute intravenous infusion

Trial Locations (2)

1010

Auckland Clinical Studies, Auckland

8011

Christchurch Clinical Studies Trust Ltd, Christchurch

Sponsors
All Listed Sponsors
lead

Prestige Biopharma Limited

INDUSTRY